Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients

Rita Alloway, Steven Steinberg, Kassem Khalil, Sita Gourishankar, Joshua Miller, Douglas Norman, Sundaram Hariharan, John Pirsch, Arthur Matas, Jeffrey Zaltzman, Kathleen Wisemandle, William Fitzsimmons, M. Roy First

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Tacrolimus extended-release (XL) is a once-daily formulation recently developed to reduce the frequency of dosing for patients currently using the twice-a-day formulation of tacrolimus (TAC). As reported previously, 67 kidney transplant recipients were safely converted (1:1 mg basis, total daily dose) from TAC twice-a-day to XL once-daily in the morning and were maintained on an am dosing regimen of XL using the same therapeutic monitoring and patient care techniques currently employed with TAC. The 2-year postconversion patient (100%) and graft (98.5%) survival, incidence of biopsy-confirmed acute rejection (6.0%), incidence of multiple rejections (1.5%), and safety profile (posttransplant diabetes, hyperlipidemia, hypertension, infections, renal dysfunction, hepatic dysfunction, and malignancies) were consistent with or more favorable than those previously reported for TAC twice-a-day.

Original languageEnglish (US)
Pages (from-to)1648-1651
Number of pages4
JournalTransplantation
Volume83
Issue number12
DOIs
StatePublished - Jun 2007

Fingerprint

Tacrolimus
Kidney
Renal Hypertension
Incidence
Graft Survival
Hyperlipidemias
Patient Care
Transplant Recipients
Biopsy
Safety
Liver
Infection
Neoplasms

Keywords

  • Conversion
  • Extended-release
  • Kidney transplant recipients
  • Tacrolimus twice-a-day
  • Two-year safety
  • XL once-daily

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. / Alloway, Rita; Steinberg, Steven; Khalil, Kassem; Gourishankar, Sita; Miller, Joshua; Norman, Douglas; Hariharan, Sundaram; Pirsch, John; Matas, Arthur; Zaltzman, Jeffrey; Wisemandle, Kathleen; Fitzsimmons, William; First, M. Roy.

In: Transplantation, Vol. 83, No. 12, 06.2007, p. 1648-1651.

Research output: Contribution to journalArticle

Alloway, R, Steinberg, S, Khalil, K, Gourishankar, S, Miller, J, Norman, D, Hariharan, S, Pirsch, J, Matas, A, Zaltzman, J, Wisemandle, K, Fitzsimmons, W & First, MR 2007, 'Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients', Transplantation, vol. 83, no. 12, pp. 1648-1651. https://doi.org/10.1097/01.tp.0000264056.20105.b4
Alloway, Rita ; Steinberg, Steven ; Khalil, Kassem ; Gourishankar, Sita ; Miller, Joshua ; Norman, Douglas ; Hariharan, Sundaram ; Pirsch, John ; Matas, Arthur ; Zaltzman, Jeffrey ; Wisemandle, Kathleen ; Fitzsimmons, William ; First, M. Roy. / Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. In: Transplantation. 2007 ; Vol. 83, No. 12. pp. 1648-1651.
@article{fefc5d2812ef4a159b0c80ce0dc47a14,
title = "Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients",
abstract = "Tacrolimus extended-release (XL) is a once-daily formulation recently developed to reduce the frequency of dosing for patients currently using the twice-a-day formulation of tacrolimus (TAC). As reported previously, 67 kidney transplant recipients were safely converted (1:1 mg basis, total daily dose) from TAC twice-a-day to XL once-daily in the morning and were maintained on an am dosing regimen of XL using the same therapeutic monitoring and patient care techniques currently employed with TAC. The 2-year postconversion patient (100{\%}) and graft (98.5{\%}) survival, incidence of biopsy-confirmed acute rejection (6.0{\%}), incidence of multiple rejections (1.5{\%}), and safety profile (posttransplant diabetes, hyperlipidemia, hypertension, infections, renal dysfunction, hepatic dysfunction, and malignancies) were consistent with or more favorable than those previously reported for TAC twice-a-day.",
keywords = "Conversion, Extended-release, Kidney transplant recipients, Tacrolimus twice-a-day, Two-year safety, XL once-daily",
author = "Rita Alloway and Steven Steinberg and Kassem Khalil and Sita Gourishankar and Joshua Miller and Douglas Norman and Sundaram Hariharan and John Pirsch and Arthur Matas and Jeffrey Zaltzman and Kathleen Wisemandle and William Fitzsimmons and First, {M. Roy}",
year = "2007",
month = "6",
doi = "10.1097/01.tp.0000264056.20105.b4",
language = "English (US)",
volume = "83",
pages = "1648--1651",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients

AU - Alloway, Rita

AU - Steinberg, Steven

AU - Khalil, Kassem

AU - Gourishankar, Sita

AU - Miller, Joshua

AU - Norman, Douglas

AU - Hariharan, Sundaram

AU - Pirsch, John

AU - Matas, Arthur

AU - Zaltzman, Jeffrey

AU - Wisemandle, Kathleen

AU - Fitzsimmons, William

AU - First, M. Roy

PY - 2007/6

Y1 - 2007/6

N2 - Tacrolimus extended-release (XL) is a once-daily formulation recently developed to reduce the frequency of dosing for patients currently using the twice-a-day formulation of tacrolimus (TAC). As reported previously, 67 kidney transplant recipients were safely converted (1:1 mg basis, total daily dose) from TAC twice-a-day to XL once-daily in the morning and were maintained on an am dosing regimen of XL using the same therapeutic monitoring and patient care techniques currently employed with TAC. The 2-year postconversion patient (100%) and graft (98.5%) survival, incidence of biopsy-confirmed acute rejection (6.0%), incidence of multiple rejections (1.5%), and safety profile (posttransplant diabetes, hyperlipidemia, hypertension, infections, renal dysfunction, hepatic dysfunction, and malignancies) were consistent with or more favorable than those previously reported for TAC twice-a-day.

AB - Tacrolimus extended-release (XL) is a once-daily formulation recently developed to reduce the frequency of dosing for patients currently using the twice-a-day formulation of tacrolimus (TAC). As reported previously, 67 kidney transplant recipients were safely converted (1:1 mg basis, total daily dose) from TAC twice-a-day to XL once-daily in the morning and were maintained on an am dosing regimen of XL using the same therapeutic monitoring and patient care techniques currently employed with TAC. The 2-year postconversion patient (100%) and graft (98.5%) survival, incidence of biopsy-confirmed acute rejection (6.0%), incidence of multiple rejections (1.5%), and safety profile (posttransplant diabetes, hyperlipidemia, hypertension, infections, renal dysfunction, hepatic dysfunction, and malignancies) were consistent with or more favorable than those previously reported for TAC twice-a-day.

KW - Conversion

KW - Extended-release

KW - Kidney transplant recipients

KW - Tacrolimus twice-a-day

KW - Two-year safety

KW - XL once-daily

UR - http://www.scopus.com/inward/record.url?scp=34250802052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250802052&partnerID=8YFLogxK

U2 - 10.1097/01.tp.0000264056.20105.b4

DO - 10.1097/01.tp.0000264056.20105.b4

M3 - Article

VL - 83

SP - 1648

EP - 1651

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 12

ER -